Method of Treating Airway Diseases With Beta-Adrenergic Inverse Agonists
First Claim
Patent Images
1. A method for treatment of pulmonary airway disease in a subject suffering from pulmonary airway disease comprising administering a therapeutically effective amount of a β
- -adrenergic inverse agonist to the subject to treat the pulmonary airway disease.
4 Assignments
0 Petitions
Accused Products
Abstract
The use of β-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method comprises administering a therapeutically effective amount of a β-adrenergic inverse agonist to the subject to treat the pulmonary airway disease. Particularly preferred inverse agonists include nadolol and carvedilol.
39 Citations
100 Claims
-
1. A method for treatment of pulmonary airway disease in a subject suffering from pulmonary airway disease comprising administering a therapeutically effective amount of a β
- -adrenergic inverse agonist to the subject to treat the pulmonary airway disease.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 16, 17, 18, 19, 20, 21, 25, 26)
-
9-15. -15. (canceled)
-
22-24. -24. (canceled)
-
27. A pharmaceutical composition comprising:
-
(a) nadolol in a quantity selected from the group consisting of 1 mg, 3 mg, 5, mg, 10 mg, 15 mg, 30 mg, 50 mg, and 70 mg; and (b) a pharmaceutically acceptable carrier.
-
-
28-39. -39. (canceled)
-
40. A method for treatment of pulmonary airway disease in a subject suffering from pulmonary airway disease comprising administering to the subject:
- (1) a therapeutically effective amount of a β
-adrenergic inverse agonist and (2) a therapeutically effective amount of an additional agent selected from the group consisting of;
a β
2-selective adrenergic agonist;
a steroid;
an anticholinergic drug;
a xanthine compound;
an anti-IgE antibody;
a leukotriene modifier; and
a phosphodiesterase inhibitor in order to treat the pulmonary airway disease. - View Dependent Claims (41, 49, 57, 65, 73, 84, 92)
- (1) a therapeutically effective amount of a β
-
42-48. -48. (canceled)
-
50-56. -56. (canceled)
-
58-64. -64. (canceled)
-
66-72. -72. (canceled)
-
74-83. -83. (canceled)
-
85-91. -91. (canceled)
-
93-98. -98. (canceled)
-
99. A pharmaceutical composition comprising:
-
(a) a therapeutically effective amount of a β
-adrenergic inverse agonist;(b) a therapeutically effective amount of a second therapeutic agent effective to treat a pulmonary airway disease, the second therapeutic agent being selected from the group consisting of a β
2-selective adrenergic agonist, a steroid, an anticholinergic drug, a xanthine compound, an anti-IgE antibody, a leukotriene modifier, and a phosphodiesterase IV inhibitor; and(c) a pharmaceutically acceptable carrier.
-
-
100-106. -106. (canceled)
Specification